The first vaccine against respiratory syncytial virus on the market arrives in Spain

Respiratory syncytial virus causes lower respiratory tract illnesses such as bronchiolitis or pneumonia. To stop its expansion, Pfizer developed the first-to-market vaccine aimed at pregnant women and women over 60 years of age. This virus accounts for more than 60% of acute respiratory infections in infants and young children worldwide. The vaccine, through immunization of the mother, gives the baby antibodies during the first six months of life, when the baby is most vulnerable. Adults can also suffer severe illness from syncytial virus, especially those who are over 60 years of age or have chronic heart disease, COPD, asthma, or are immunocompromised. The vaccine is now available in Spain and should be used in accordance with official recommendations. It is given as a single dose to pregnant women between 24 and 36 weeks’ gestation. As for the indications for active immunization of persons over 60 years of age for the prevention of RSV disease, they are not included in the reimbursement of the General Pharmacy Directorate.